By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Orexigen Therapeutics, Inc. 

48 Wall Street
Suite 1100
New York  New York  10005  U.S.A.
Phone: 212-918-4650 Fax: 212-918-4801



Company News
Orexigen Therapeutics, Inc. (OREX) Announces Contrave┬« (naltrexone HCI And Bupropion HCI Extended Release) Data Presentations At The ObesityWeek Meeting In Boston 10/31/2014 7:32:20 AM
Takeda Pharmaceuticals And Orexigen Therapeutics, Inc. (OREX) Announce Availability Of CONTRAVE┬« (naltrexone HCI And bupropion HCI) Extended-Release Tablets For Chronic Weight Management In Obese Adults 10/20/2014 8:22:26 AM
Orexigen Therapeutics, Inc. (OREX) Pockets $100 Million Milestone Payment From Takeda Pharmaceutical Co. Ltd. (TKPYY) 10/15/2014 7:00:15 AM
Orexigen Therapeutics, Inc. (OREX) To Present At The Bank of America (BAC) Merrill Lynch Global Healthcare Conference 9/17/2014 8:06:03 AM
Orexigen Therapeutics, Inc. (OREX) To Host Conference Call And Webcast At 8:30 AM Eastern Time September 11, 2014 9/11/2014 8:14:22 AM
FDA Approves Orexigen Therapeutics, Inc. (OREX)'s Long-Awaited Weight Loss Drug Contrave 9/11/2014 5:59:03 AM
Orexigen Therapeutics, Inc. (OREX), Novo Nordisk A/S (NVO) Seek To Enter Still Struggling Obesity Market This Week 9/9/2014 6:44:20 AM
Orexigen Therapeutics, Inc. (OREX) Expands NB32 Intellectual Property Portfolio With New U.S. Patent 9/3/2014 11:23:32 AM
Orexigen Therapeutics, Inc. (OREX) Reports Corporate And Financial Results For The Second Quarter Ended June 30, 2014 8/7/2014 9:31:40 AM
Orexigen Therapeutics, Inc. (OREX) To Host Second Quarter 2014 Financial Results Conference Call And Webcast 7/31/2014 9:38:41 AM